Back to Search
Start Over
Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder.
- Source :
-
Journal of child and adolescent psychopharmacology [J Child Adolesc Psychopharmacol] 2010 Aug; Vol. 20 (4), pp. 347-53. - Publication Year :
- 2010
-
Abstract
- Selective serotonin reuptake inhibitors (SSRIs) are usually well tolerated in the pediatric population, and widely used in the treatment of obsessive-compulsive disorder (OCD). Of the 51 pediatric patients with obsessive-compulsive disorder seen in our outpatient clinic between January 2009 and July 2009, 3 of them developed behavioral disinhibition after treatment with fluvoxamine. These cases are described and discussed in relation to the use of CYP2D6 and CYP2C19 pharmacogenetic testing in patients treated with serotonin-selective reuptake inhibitors.
- Subjects :
- Aryl Hydrocarbon Hydroxylases metabolism
Child
Cytochrome P-450 CYP2C19
Cytochrome P-450 CYP2D6 metabolism
Fluvoxamine therapeutic use
Humans
Inhibition, Psychological
Male
Obsessive-Compulsive Disorder drug therapy
Pharmacogenetics
Selective Serotonin Reuptake Inhibitors therapeutic use
Fluvoxamine adverse effects
Impulsive Behavior chemically induced
Selective Serotonin Reuptake Inhibitors adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1557-8992
- Volume :
- 20
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Journal of child and adolescent psychopharmacology
- Publication Type :
- Report
- Accession number :
- 20807074
- Full Text :
- https://doi.org/10.1089/cap.2009.0126